The MarketReader Minute
💊 Biotech Breakthroughs Propel Market: Applied Therapeutics Soars, Immunic Rises and Opthea Advances AMD Treatment Milestones | Biotech Sector Insights
HC Wainwright & Co. reiterated a Buy rating on Exelixis, setting a price target of $29, backed by an average 12-month target of $29.4. Exelixis reported a robust revenue growth rate of over 35% as of June 30, 2024, alongside strong financial metrics, including a net margin exceeding 35%.